Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Tratamiento farmacológico antiinflamatorio no esteroide oral para la fibrosis quística

Esta versión no es la más reciente

Información

DOI:
https://doi.org/10.1002/14651858.CD001505.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 17 octubre 2007see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Fibrosis quística y enfermedades genéticas

Copyright:
  1. Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Larry C Lands

    Correspondencia a: Department of Pediatrics, Montreal Children's Hospital, Montreal, Canada

    [email protected]

  • Sanja Stanojevic

    CHild Health Evaluative Sciences & Respiratory Medicine, The Hospital for Sick Children, Toronto, Canada

Contributions of authors

Anna Crighton had the original idea for the review, drafted the protocol, extracted data and co‐authored the review. Carol Dezateux drafted the protocol and data extraction forms, extracted and analyzed data and was responsible for writing the review.

Anna Crighton and Carol Dezateux stepped down from the review as from February 2006.

Larry Lands took over as lead reviewer in May 2004. He led on the update of the review and acts as guarantor of the review.

Sanja Stanojevic joined the review in June 2006. She extracted and analyzed data for the subsequent updates and co‐authored the review.

Sources of support

Internal sources

  • Institute of Child Health, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.

External sources

  • Tenovus, Scotland, UK.

Declaraciones de interés

disponible en

Dr Larry Lands fue el investigador principal en el Ensayo transcanadiense (Lands 2007)).

Agradecimientos

disponible en

Se agradece al profesor Ros Smyth, a Jill Motley, a Nikki Jahnke y al Grupo Cochrane Editorial de Fibrosis Quística y Trastornos Genéticos (Cochrane Cystic Fibrosis and Genetic Disorders Editorial Group) por su apoyo valioso; a la profesora Carol Dezateux y a Anna Crighton por sus aportaciones a las versiones anteriores de esta revisión; al Dr. Michael Konstan por sus observaciones útiles sobre un borrador anterior de la revisión original; y al Dr. Somnath Mukhopadhyay por su estímulo.

Version history

Published

Title

Stage

Authors

Version

2019 Sep 09

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis

Review

Larry C Lands, Sanja Stanojevic

https://doi.org/10.1002/14651858.CD001505.pub5

2016 Apr 07

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis

Review

Larry C Lands, Sanja Stanojevic

https://doi.org/10.1002/14651858.CD001505.pub4

2013 Jun 13

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis

Review

Larry C Lands, Sanja Stanojevic

https://doi.org/10.1002/14651858.CD001505.pub3

2007 Oct 17

Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis

Review

Larry C Lands, Sanja Stanojevic

https://doi.org/10.1002/14651858.CD001505.pub2

1999 Apr 26

Oral non‐steroidal anti‐inflammatory drug therapy for cystic fibrosis

Review

Larry C Lands, Carol Dezateux, A Crighton, Sanja Stanojevic

https://doi.org/10.1002/14651858.CD001505

Differences between protocol and review

There was a post‐hoc subgroup analysis of the lung function data split by age (two groups: 'under 13 years at randomisation' and '13 years and over at randomisation').

Keywords

MeSH

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 1 Annual rate of change in % predicted FEV1.
Figuras y tablas -
Analysis 1.1

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 1 Annual rate of change in % predicted FEV1.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 2 Annual rate of change in % predicted FEV1 (split by age).
Figuras y tablas -
Analysis 1.2

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 2 Annual rate of change in % predicted FEV1 (split by age).

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 3 Annual rate of change in % predicted FVC.
Figuras y tablas -
Analysis 1.3

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 3 Annual rate of change in % predicted FVC.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 4 Annual rate of change in % predicted FVC (split by age).
Figuras y tablas -
Analysis 1.4

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 4 Annual rate of change in % predicted FVC (split by age).

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 5 Annual rate of change in % predicted FEF25‐75%.
Figuras y tablas -
Analysis 1.5

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 5 Annual rate of change in % predicted FEF25‐75%.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 6 Annual rate of change in % predicted FEF25‐75% (split by age).
Figuras y tablas -
Analysis 1.6

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 6 Annual rate of change in % predicted FEF25‐75% (split by age).

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 7 Proportion with at least one respiratory hospitalisation.
Figuras y tablas -
Analysis 1.7

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 7 Proportion with at least one respiratory hospitalisation.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 8 Proportion with at least one hospital admission.
Figuras y tablas -
Analysis 1.8

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 8 Proportion with at least one hospital admission.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 9 Number of deaths.
Figuras y tablas -
Analysis 1.9

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 9 Number of deaths.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 10 Annual rate of change in % ideal body weight.
Figuras y tablas -
Analysis 1.10

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 10 Annual rate of change in % ideal body weight.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 11 Annual rate of change in % ideal body weight (split by age).
Figuras y tablas -
Analysis 1.11

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 11 Annual rate of change in % ideal body weight (split by age).

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 12 Chest X‐ray score.
Figuras y tablas -
Analysis 1.12

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 12 Chest X‐ray score.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 13 Chest X‐ray score (split by age).
Figuras y tablas -
Analysis 1.13

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 13 Chest X‐ray score (split by age).

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 14 Increase in abdominal pain.
Figuras y tablas -
Analysis 1.14

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 14 Increase in abdominal pain.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 15 Decrease in abdominal pain.
Figuras y tablas -
Analysis 1.15

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 15 Decrease in abdominal pain.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 16 Proportion with at least one gastrointestinal hospitalisation.
Figuras y tablas -
Analysis 1.16

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 16 Proportion with at least one gastrointestinal hospitalisation.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 17 Stool frequency.
Figuras y tablas -
Analysis 1.17

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 17 Stool frequency.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 18 Occult blood.
Figuras y tablas -
Analysis 1.18

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 18 Occult blood.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 19 Increase in epistaxis.
Figuras y tablas -
Analysis 1.19

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 19 Increase in epistaxis.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 20 Decrease in epistaxis.
Figuras y tablas -
Analysis 1.20

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 20 Decrease in epistaxis.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 21 Increase in conjunctivitis.
Figuras y tablas -
Analysis 1.21

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 21 Increase in conjunctivitis.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 22 Decrease in conjunctivitis.
Figuras y tablas -
Analysis 1.22

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 22 Decrease in conjunctivitis.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 23 Increase in nausea.
Figuras y tablas -
Analysis 1.23

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 23 Increase in nausea.

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 24 Increase in diarrhoea.
Figuras y tablas -
Analysis 1.24

Comparison 1 Oral nonsteroidal anti‐inflammatory drug versus placebo, Outcome 24 Increase in diarrhoea.

Comparison 1. Oral nonsteroidal anti‐inflammatory drug versus placebo

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Annual rate of change in % predicted FEV1 Show forest plot

2

226

Mean Difference (IV, Fixed, 95% CI)

1.32 [0.21, 2.42]

2 Annual rate of change in % predicted FEV1 (split by age) Show forest plot

2

226

Mean Difference (IV, Fixed, 95% CI)

1.16 [0.07, 2.25]

2.1 Under 13 years at randomisation

2

147

Mean Difference (IV, Fixed, 95% CI)

1.41 [0.03, 2.80]

2.2 13 years or over at randomisation

2

79

Mean Difference (IV, Fixed, 95% CI)

0.75 [‐1.02, 2.52]

3 Annual rate of change in % predicted FVC Show forest plot

2

226

Mean Difference (IV, Fixed, 95% CI)

1.27 [0.26, 2.28]

4 Annual rate of change in % predicted FVC (split by age) Show forest plot

2

226

Mean Difference (IV, Fixed, 95% CI)

1.09 [0.12, 2.06]

4.1 Under 13 years at randomisation

2

147

Mean Difference (IV, Fixed, 95% CI)

1.32 [0.04, 2.60]

4.2 13 years and over at randomisation

2

79

Mean Difference (IV, Fixed, 95% CI)

0.78 [‐0.71, 2.27]

5 Annual rate of change in % predicted FEF25‐75% Show forest plot

2

218

Mean Difference (IV, Fixed, 95% CI)

1.80 [0.15, 3.45]

6 Annual rate of change in % predicted FEF25‐75% (split by age) Show forest plot

2

214

Mean Difference (IV, Fixed, 95% CI)

1.72 [0.10, 3.34]

6.1 Under 13 years at randomisation

2

138

Mean Difference (IV, Fixed, 95% CI)

2.03 [‐0.09, 4.16]

6.2 13 years or older at randomisation

2

76

Mean Difference (IV, Fixed, 95% CI)

1.28 [‐1.22, 3.79]

7 Proportion with at least one respiratory hospitalisation Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

8 Proportion with at least one hospital admission Show forest plot

4

286

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.61 [0.37, 1.01]

9 Number of deaths Show forest plot

3

245

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.0 [0.0, 0.0]

10 Annual rate of change in % ideal body weight Show forest plot

1

Mean Difference (IV, Fixed, 95% CI)

Totals not selected

11 Annual rate of change in % ideal body weight (split by age) Show forest plot

1

84

Mean Difference (IV, Fixed, 95% CI)

0.81 [0.08, 1.53]

11.1 Under 13 years at randomisation

1

49

Mean Difference (IV, Fixed, 95% CI)

1.45 [0.33, 2.57]

11.2 13 years or older at randomisation

1

35

Mean Difference (IV, Fixed, 95% CI)

0.34 [‐0.61, 1.29]

12 Chest X‐ray score Show forest plot

2

226

Mean Difference (IV, Fixed, 95% CI)

0.37 [‐0.08, 0.81]

13 Chest X‐ray score (split by age) Show forest plot

1

84

Mean Difference (IV, Fixed, 95% CI)

0.51 [‐0.04, 1.07]

13.1 Under 13 years at randomisation

1

49

Mean Difference (IV, Fixed, 95% CI)

0.45 [‐0.24, 1.14]

13.2 13 years or older at randomisation

1

35

Mean Difference (IV, Fixed, 95% CI)

0.63 [‐0.30, 1.56]

14 Increase in abdominal pain Show forest plot

2

226

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.54 [0.20, 1.48]

15 Decrease in abdominal pain Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

16 Proportion with at least one gastrointestinal hospitalisation Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

17 Stool frequency Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

18 Occult blood Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

19 Increase in epistaxis Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

20 Decrease in epistaxis Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

21 Increase in conjunctivitis Show forest plot

2

226

Peto Odds Ratio (Peto, Fixed, 95% CI)

0.72 [0.22, 2.40]

22 Decrease in conjunctivitis Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

23 Increase in nausea Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

24 Increase in diarrhoea Show forest plot

1

Peto Odds Ratio (Peto, Fixed, 95% CI)

Totals not selected

Figuras y tablas -
Comparison 1. Oral nonsteroidal anti‐inflammatory drug versus placebo